バイオインフォマティクス市場における世界の AI - 2030 年までの業界動向と予測

バイオインフォマティクスにおける AI の市場分析と規模

遺伝子配列決定コストの削減により、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に起因しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げとサービスの承認に重点を置いています。さらに、バイオインフォマティクスの需要の高まりと、バイオインフォマティクスに対する官民セクターの資金の増加も、市場の需要の高まりに貢献しています。

バイオインフォマティクスにおける AI 市場は、市場プレーヤーの増加と高度なサービスの利用可能性により、予測年度に成長しています。これに伴い、メーカーは市場に新しいサービスを立ち上げるための研究開発活動に取り組んでいます。バイオインフォマティクス技術の進歩が進むことで、市場の成長がさらに加速しています。ただし、バイオインフォマティクスにおける計測機器の高コストとサイバーセキュリティの懸念により、予測期間中のバイオインフォマティクスにおける AI 市場の成長が妨げられる可能性があります。

Data Bridge Market Researchは、バイオインフォマティクスにおける世界のAI市場は2022年に253万米ドルと評価され、2030年までに2億1,738万米ドルに達し、2023～2030年の予測期間中に42.7%のCAGRを記録すると分析しています。バイオインフォマティクスにおけるハンドヘルドAIの使用を商業化する技術経路が急速に発展しているため、「サービス」はバイオインフォマティクスにおけるAI市場で最大の技術セグメントを占めています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

レポートの範囲と市場セグメンテーション

Market Definition

Bioinformatics is a sub-discipline that has to do with the analysis of sequences of biological molecules. It usually refers to genes, DNA, RNA, or protein and is particularly useful in comparing genes and other sequences in proteins and different sequences within an organism or between organisms, looking at the evolutionary relationships between organisms and using the patterns that exist across DNA and protein sequences to figure out what their function is.

Bioinformatics combines computer programming, big data and molecular biology, which enables scientists to understand and identify patterns in biological data. It is particularly useful in studying genomes and DNA sequencing, as it allows scientists to organize large amounts of data.

From genetics to toxicology to mycology and radiobiology, there are scores of branches of biology to specialize in. And out of the many, bioinformatics is one of the intriguing fields which enables you to identify, evaluate, store and retrieve biological information. Being an interdisciplinary field of study, it incorporates various applications of computer science, statistics and biology to develop software applications for understanding biological data like DNA sequencing, protein analysis, evolutionary genetics and others.

In the coming future, important decisions related to bioinformatics on drug discovery will be made by individuals who not only understand biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify the quality target.

Global AI in Bioinformatics Market Dynamics

Drivers

• Growing demand for bioinformatics

As genomics focused, pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight into molecular underpinnings of individual tumors and specific receptors. Informatics is essential in biological research, which involves biologists who learn programming, or computer programmers, mathematicians, or database managers to learn the foundations of biology.

• Reduction in the genetic sequencing cost

The strong demand for decreasing the cost of genomics and biomarker prediction has contributed to the creation of high-throughput genome sequencing, which often goes by the name next-generation sequencing (NGS). Thousands or millions of sequences in a single bioinformatics cycle are generated simultaneously. Dramatic upgrades to industrial NGS technologies have culminated in dramatic cutbacks in DNA sequencing cost-per-base. Thus recently, the main sequencing techniques have become the key subject of research, with sample design optimization taking a secondary function.

• Increasing public-private sector funding for bioinformatics

In order to improve the workflow for bioinformatics, the federal agencies, the public and the private agencies are providing funds in order to carry out bioinformatics projects and to scientists for research purposes. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes. Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which, in turn, have improved the quality of these services.

 Opportunities

• Strategic initiatives of key players

The dramatic rise in the quality of research coupled with increasing research opportunities is because of various strategic initiatives taken by key market players. They are taking initiatives such as product launches, collaborations, mergers, acquisitions and many more over the years and are expected to lead and create more opportunities in the market.

By successfully working with new technology firms to ensure continued growth, creativity and viability in the industry, healthcare product suppliers have a huge opportunity. Health enterprises that implement technology-enabled technologies will explore new modes of goods for patient care, streamline processes and engage patients more.

Companies to discover and develop advanced bioinformatics products and these companies are launching new initiatives and collaborating with other key players to deliver more reliable results and services.

• Advancement in bioinformatics technology

The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, AI based bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology, up-gradation of instruments and techniques is also needed, moreover, the bioinformatics market has a vast potential to upgrade in various applications and there are high chances of the advancement of bioinformatics techniques in the forecasted period.

 Restraints/Challenges

• High cost of instrumentation

The cost of the device plays a major factor in the market. The AI based bioinformatics instrument is highly sophisticated and needs high validation and other specification, which increase. Genomics instruments are also equipped with advanced features and functionalities and are thus priced at a premium, ranging between USD 10–20 million. As pharmaceutical companies and research laboratories require many such systems, their capital expenditure on procuring multiple genomic instruments is very high. In the case of small and medium-sized pharmaceutical companies and research laboratories, it is not feasible for them to make such high investments in multiple genomics instruments. Hence, the high cost of AI based equipment is expected to restrain the market growth.

• Lack of skilled professionals to perform AI based bioinformatics technology

One of biology's most rapidly developing fields of study is bioinformatics, which involves developing and using computational tools for collecting, archiving, organizing, analyzing, and visualizing biological data. The advancement of technology has made it possible to reach the level of next-generation analysis from conventional data analysis methods. The advancement of the technology of bioinformatics requires various skill sets for its handling. As the bioinformatics platforms are highly automated and costly machines, the improper handling of such machines can damage their parts which can hamper achieving analysis and visualisation of biological data. Thereby, it will proportionally hamper the result of data processing. The dearth of skilled professionals having adequate skills and knowledge to perform next-generation sequencing, therefore, hampers the growth of the market.

This AI in bioinformatics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the AI in bioinformatics market contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In June 2022, SOPHiA GENETICS, a leader in data-driven medicine, announced at the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications. With this certification, the SOPHiA DDM™ Platform is now IVD-ready to support all applications and modules designed for diagnostic purposes in the European Union and other markets recognizing this certification. This has helped the company to increase its global presence in the market
• In December 2021, JADBio and BioLizard announced their partnership. BioLizard is agile bioinformatics and AI/ML company globally servicing clients in the life sciences, biotechnology and pharmaceutical industries. JADBio is a robust Automated Machine Learning platform that allows intuitive, timely and interactive creation of ML predictive models on BioMedical and Multi-omics data while allowing for knowledge (biomarker signature) discovery through its vast range of reporting and analysis. This has helped the company to expand its products and services portfolio in the market.

Global AI in Bioinformatics Market Scope

The AI in bioinformatics market is segmented on the basis of offering, type, products and services, application and sector. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

• Services
•  Software
•  Others

Type

• Machine Learning
• Deep Learning
• Others

Products and Services

• Bioinformatics Services
• Bioinformatics Platforms
• Knowledge Management Tools

Application

• Genomics
• Chemoinformatics & Drug Design
• Proteomics
• DNA Sequencing
• System Biology
• Transcriptomics
• Text Mining
• Microarrays
• Metabolomics
• Others

Sector

• Medical Biotechnology
• Animal Biotechnology
• Plant Biotechnology
• Environmental Biotechnology
• Forensic Biotechnology
• Others

Global AI in Bioinformatics Analysis/Insights

The AI in bioinformatics market is analyzed and market size insights and trends are provided by country, offering, type, products and services, application and sector as referenced above.

The countries covered in the  AI in bioinformatics market report are U.S., Canada, Mexico in North America, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, rest of Europe in Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, rest of Asia-Pacific in Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and rest of Middle East and Africa (MEA) in Middle East and Africa, Brazil, Argentina and rest of South America in South America.

North America is expected to dominate the global AI in bioinformatics market due to the rising demand for advanced technology and drug development & design, which have accelerated the market growth. To cope with the increasing demand, companies and market players are initiating various strategies such as product launch, advancement, acquisition agreements and others which is expected to dive the market growth.

Asia-Pacific is expected to show significant growth in AI in Bioinformatics market during the forecast period of 2023 to 203o due to rapidly increasing government investments in healthcare infrastructure and AI research.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and AI in Bioinformatics Market Share Analysis

The AI in bioinformatics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus on the AI in bioinformatics market.

The major players covered in the AI in bioinformatics market report are:

• JADBio (U.S.)
• Gnosis Data Analysis (Israel)
• Fios Genomics (U.K.)
• SOPHiA GENETICS (Switzerland)
• Biomax Informatics Inc. (U.S.)
• DNASTAR (U.S.)
• Ardigen (Parent Company Selvita Group) (Poland)
• Source BioScience (U.K.)
• QIAGEN (Germany)
• NeoGenomics Laboratories (U.S.)
• CelbridgeScience (U.S.)
• Eurofins Scientific (Luxembourg)
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)
• Insilico Medicine (U.S.)
• Strand Life Sciences (India)
• Dassault Systèmes (France)
• iNDX.Ai (U.S.)
• Paige AI, Inc. (U.S.)
• ソマロジック・オペレーティング社（米国）

SKU-69028